In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $10.64 in the last session, up 5.98% from day before closing price of $10.04. In other words, the price has increased by $5.98 from its previous closing price. On the day, 0.87 million shares were traded.
Ratios:
We take a closer look at NRIX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.26 and its Current Ratio is at 6.26. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 17, 2025, initiated with a Market Perform rating and assigned the stock a target price of $16.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $35 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 02 ’25 when van Houte Hans sold 6,198 shares for $11.33 per share. The transaction valued at 70,243 led to the insider holds 33,724 shares of the business.
JOHANNES VAN HOUTE bought 6,198 shares of NRIX for $69,170 on May 02 ’25. On Apr 30 ’25, another insider, Hansen Gwenn, who serves as the Chief Scientific Officer of the company, sold 3,377 shares for $11.50 each. As a result, the insider received 38,841 and left with 61,516 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 14.38 while its Price-to-Book (P/B) ratio in mrq is 1.69.
Stock Price History:
Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is -0.56%, while the 200-Day Moving Average is calculated to be -42.89%.
Shares Statistics:
A total of 76.23M shares are outstanding, with a floating share count of 74.71M. Insiders hold about 2.00% of the company’s shares, while institutions hold 110.13% stake in the company.
Earnings Estimates
The performance of Nurix Therapeutics Inc (NRIX) in the stock market is under the watchful eye of 15.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.8, with high estimates of -$0.7 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.79 and -$3.56 for the fiscal current year, implying an average EPS of -$3.08. EPS for the following year is -$3.31, with 14.0 analysts recommending between -$1.62 and -$4.6.
Revenue Estimates
A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $89.28M, while the lowest revenue estimate was $18.5M, resulting in an average revenue estimate of $63.12M. In the same quarter a year ago, actual revenue was $54.55M
